Treatment of Ochrobactrum Infection
For Ochrobactrum anthropi infections, treat with either intravenous cefepime, imipenem-cilastatin, or oral ciprofloxacin/trimethoprim-sulfamethoxazole based on susceptibility testing, combined with surgical debridement when indicated, particularly for catheter-related or deep tissue infections.
Antimicrobial Selection
First-Line Options (Based on Susceptibility)
Intravenous therapy is preferred for severe infections:
Oral therapy for less severe infections or step-down:
Combination Therapy Considerations
Empiric combinations including ciprofloxacin and/or trimethoprim-sulfamethoxazole may be useful while awaiting susceptibility results 3. Aminoglycosides (gentamicin, amikacin) show consistent activity and can be used in combination 2.
Critical Resistance Pattern
Ochrobactrum is intrinsically resistant to multiple beta-lactams 3, 2:
- Ampicillin
- First-generation cephalosporins (cephalothin)
- Amoxicillin-clavulanate
- Piperacillin
- Aztreonam
- Ceftazidime
Do not use these agents empirically - they will fail despite in vitro susceptibility in some cases 4.
Surgical Management
Catheter removal is often necessary for cure, particularly in catheter-related bloodstream infections 5, 4. One case demonstrated persistent bacteremia despite appropriate antibiotics until catheter removal 4. For deep tissue infections (hand, bone), surgical debridement is essential - antibiotics alone are frequently insufficient 1, 6.
Treatment Duration
- Intravenous therapy: 15 days for soft tissue infections 1
- Oral step-down: Additional 2 weeks 1
- Osteomyelitis: Prolonged therapy following extensive surgical debridement 6
Clinical Context
Ochrobactrum anthropi is a low-virulence opportunistic pathogen that causes infections in:
- Immunocompromised patients (most common)
- Patients with indwelling catheters 2, 5
- Immunocompetent hosts (increasingly recognized) 1, 2, 4
The organism has environmental sources (soil, water) and affinity for aquatic environments and plastic devices 7. Community-acquired infections occur, particularly with environmental exposure like gardening 1.
Key Pitfalls
Discrepancies between in vitro susceptibility and in vivo efficacy are well-documented 4. Even with susceptible organisms, clinical failure can occur without source control (catheter removal, debridement). Do not rely on empiric beta-lactam therapy without susceptibility confirmation - resistance patterns are unpredictable 4.
The organism may be misidentified as Brucella species due to close genetic relationship 3, so confirm identification if clinical picture doesn't fit.
Monitoring
Expect fever resolution within 4 days on average (range 0-11 days) 2. Persistent fever or bacteremia despite appropriate antibiotics mandates re-evaluation for source control (retained catheter, undrained abscess, inadequate debridement).